Saul M. Genuth

Saul M. Genuth's AcademicInfluence.com Rankings

Saul M. Genuth

Philosophy

#6493

World Rank

#9537

Historical Rank

Logic

#3648

World Rank

#4840

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Saul M. Genuth's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Saul M. Genuth Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Saul M. Genuth's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus (1993) (19715)
Report of the expert committee on the diagnosis and classification of diabetes mellitus. (1999) (11399)
Effects of intensive glucose lowering in type 2 diabetes. (2008) (4946)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. (2005) (4036)
Follow-up report on the diagnosis of diabetes mellitus. (2003) (3690)
International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes (2009) (2534)
A randomized trial of therapies for type 2 diabetes and coronary artery disease. (2009) (1778)
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. (2000) (1434)
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial (2010) (1192)
Effects of medical therapies on retinopathy progression in type 2 diabetes. (2010) (1073)
Long-term effects of intensive glucose lowering on cardiovascular outcomes. (2011) (950)
Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. (2003) (832)
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. (2002) (816)
Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). (2009) (594)
Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. (1999) (552)
Lowering the criterion for impaired fasting glucose is in order. (2003) (541)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. (2007) (530)
Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited (2008) (460)
Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro (1999) (441)
Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial (2010) (431)
The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study (2010) (420)
Diabetes Control and Complications Trial (DCCT): Results of Feasibility Study. The DCCT Research Group (1987) (415)
Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. (2005) (407)
Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials (2011) (393)
Implications of the United kingdom prospective diabetes study. (2003) (300)
The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study (2006) (258)
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions (2013) (247)
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. (2007) (234)
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. (2014) (232)
Evaluating the Role of Epigenetic Histone Modifications in the Metabolic Memory of Type 1 Diabetes (2014) (196)
Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort (2016) (173)
Glycation Products as Markers and Predictors of the Progression of Diabetic Complications (2005) (166)
Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. (2006) (154)
Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes (2016) (148)
Insulin Use in NIDDM (1990) (136)
Plasma insulin and glucose profiles in normal, obese, and diabetic persons. (1973) (133)
Development and validation of GFR-estimating equations using diabetes, transplant and weight. (2010) (126)
Insulin resistance in genetically obese, hyperglycemic mice. (1971) (122)
Weight reduction in obesity by outpatient semistarvation. (1974) (118)
Skin Advanced Glycation End Products Glucosepane and Methylglyoxal Hydroimidazolone Are Independently Associated With Long-term Microvascular Complication Progression of Type 1 Diabetes (2014) (112)
Carnitine metabolism in normal-weight and obese human subjects during fasting. (1980) (107)
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study (2016) (104)
Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT). (2010) (102)
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. (2006) (101)
Classification and diagnosis of diabetes mellitus. (1982) (97)
Effect of dietery weight loss on sex steroid binding sex steroids, and gonadotropins in obese postmenopausal women. (1979) (93)
Exogenous Insulin Administration and Cardiovascular Risk in Non-Insulin-dependent and Insulin-dependent Diabetes Mellitus (1996) (92)
Control of Hyperglycemia in Adult Diabetics by Pulsed Insulin Delivery (1977) (87)
Metabolic Clearance of Insulin in Man (1972) (85)
Myocardial Structure, Function, and Scar in Patients With Type 1 Diabetes Mellitus (2011) (83)
Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study (2016) (81)
Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial (2011) (73)
Plasma and Urine Carnitine in Diabetic Ketosis (1979) (72)
Supplemented fasting as a large-scale outpatient program. (1977) (72)
The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial (2007) (71)
Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial (2013) (67)
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. (2012) (66)
Aldosterone secretion in anephric patients. (1972) (62)
Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). (2007) (61)
Comparative response to parathyroid hormone in hyperthyroidism and hypothyroidism. (1975) (60)
Forum One: Current Recommendations about Intensification of Metabolic Control in Non-Insulin-dependent Diabetes Mellitus (1996) (60)
A RADIOIMMUNOLOGICAL ASSAY METHOD FOR INSULIN USING INSULIN-125I AND GEL FILTRATION. (1965) (59)
Clinical implications of the ACCORD trial. (2012) (58)
Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications (2014) (57)
Implications of the Diabetes Control and Complications Trial. (2003) (56)
The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. (2013) (52)
Supplemented fasting in the treatment of obesity and diabetes. (1979) (50)
Baseline Characteristics of Patients with Diabetes and Coronary Artery Disease Enrolled in the BARI 2D Trial (2008) (50)
Constant intravenous insulin infusion in diabetic ketoacidosis. (1973) (49)
Hyperinsulinism in mice with genetically determined obesity. (1969) (49)
Functioning primary thyroid carcinoma and metastases producing hyperthyroidism. (1971) (49)
Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s Time to Move On! (2014) (49)
Osteomalacia accompanying chronic anticonvulsant therapy. (1972) (48)
STIMULATION OF INSULIN RELEASE BY CORICOTROPIN. (1965) (45)
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes (2015) (44)
Coprogression of Cardiovascular Risk Factors in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study (2016) (43)
Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. (2008) (43)
The case for blood glucose control. (1995) (41)
Haptoglobin Genotype and the Rate of Renal Function Decline in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (2013) (39)
Effect of dexamethasone on oral glucose tolerance in healthy adults. (2010) (38)
Report and Recommendations of the San Antonio Conference on Diabetic Neuropathy (1988) (38)
The UKPDS and its global impact (2008) (37)
Binding of Insulin by Monkey and Pig Hypothalamus (1983) (37)
Urinary excretion of acetylcarnitine during human diabetic and fasting ketosis. (1982) (36)
Effects of Prior Intensive Versus Conventional Therapy and History of Glycemia on Cardiac Function in Type 1 Diabetes in the DCCT/EDIC (2013) (36)
Effects of Prolonged Fasting on Insulin Secretion (1966) (35)
Plasma parathormone, calcium and phosphorus in patients with renal osteodystrophy undergoing chronic hemodialysis. (1970) (34)
Long-term effect of diabetes and its treatment on cognitive function (2007) (34)
Insulin Dose and Cardiovascular Mortality in the ACCORD Trial (2015) (34)
Clinical Remission in Diabetes Mellitus: Studies of Insulin Secretion (1970) (33)
Insulin secretion in obesity and diabetes: an illustrative case. (1977) (32)
Acute hormonal effects on carnitine metabolism in thin and obese subjects: responses to somatostatin, glucagon, and insulin. (1981) (30)
Effect of oral alanine on blood beta-hydroxybutyrate and plasma glucose, insulin, free fatty acids, and growth hormone in normal and diabetic subjects. (1974) (30)
Multiple endocrine adenomas in a patient with the Maffucci syndrome. (1976) (29)
Effects of oral alanine administration in fasting obese subjects. (1973) (29)
Management of the adult onset diabetic with sulfonylurea drug failure. (1992) (27)
Self-reported prevalence of diabetes screening in the U.S., 2005-2010. (2014) (27)
Laxative-induced hypokalemia, sodium depletion and hyperreninemia. Effects of potassium and sodium replacement on the renin-angiotensin-aldosterone system. (1975) (26)
The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes (2016) (25)
Hypoparathyroidism and Paget's disease: the effect of parathyroid hormone administration. (1972) (24)
Hyperinsulinism in obese diabetic Pima Indians. (1967) (24)
Oral calcium absorption in patients with renal failure treated by chronic hemodialysis. (1969) (24)
DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes (2020) (24)
Observations on the Value of Mass Indiscriminate Screening for Diabetes Mellitus Based on a Five-year Follow-up (1978) (22)
Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes (2016) (21)
Therapeutic controversy: Pancreas transplantation for type I diabetes. (1998) (21)
Unilateral renal plasma flow in the assessment of correctable renovascular hypertension. (1965) (20)
Clinical Diabetes Mellitus—A Problem-Oriented Approach (1987) (19)
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study: 30th Anniversary Presentations (2013) (19)
A Step Backward—or Is it Forward? The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the American Diabetes Association. (2008) (19)
Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes: response to McCarter et al. (2005) (19)
Relationships between the structure and biological activities of corticotropin and related peptides: hyperglycemic action of N-acetylated corticotropin related peptides. (1966) (18)
Pancreas Transplantation for Type 1 Diabetes— A Summation (1998) (18)
CARNITINE AND CARNITINE PALMITOYLTRANSFERASE IN METABOLIC STUDIES1 (1980) (17)
Potentiation of levodopa stimulation of human growth hormone by systemic decarboxylase inhibition (1973) (16)
Experience with low-dose insulin infusion in diabetic ketoacidosis and diabetic hyperosmolarity. (1978) (15)
Quantitation of the pathways of fructose metabolism in normal and fructose-intolerant subjects. (1971) (15)
Persistent hypoglycemia and hyperinsulinemia: caution in using glucagon. (1996) (15)
Pancreas transplantation for type I diabetes (1998) (14)
Diabetic ketoacidosis and hyperglycemic hyperosmolar coma. (1994) (14)
Evolution of the study coordinator role: The 28-year experience in Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) (2012) (13)
Review of three decades of laboratory exercises in the preclinical curriculum at the Case Western Reserve University School of Medicine (1992) (13)
DEMONSTRATION OF IMMUNOLOGICAL SIMILARITIES OF HUMAN PREGNANCY GONADOTROPIN AND CHORIOCARCINOMA GONADOTROPIN WITH ANTISERA PREPARED IN RABBITS AND MONKEYS. (1964) (13)
Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D (2015) (13)
Community Screening for Diabetes by Blood Glucose Measurement: Results of a Five-year Experience (1976) (13)
Normalization of Insulin Delivery to Diabetics by Pulsed Insulin Infusion (1977) (12)
Urinary 3-hydroxyadipic acid 3,6-lactone: structural identification and effect of fasting in adults and children. (1989) (12)
Simplified measurement of glomerular filtration rate. (1971) (12)
Implications of the United Kingdom prospective diabetes study for patients with obesity and type 2 diabetes. (2000) (12)
Effect of high fat vs. high carbohydrate feeding on the development of obesity in weanling ob/ob mice (1976) (9)
Insulin response to intravenous alimentation. (1973) (9)
Factitious Diabetic Instability (1985) (9)
Diabetes Management in the 80s: The Role of Home Blood Glucose Monitoring and New Insulin Delivery Systems (1983) (9)
Diabetic ketoacidosis and hyperglycemic hyperosmolar coma. (1997) (8)
Precautions with supplemented fasting. (1977) (8)
Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC (2022) (8)
A case of idiopathic hypoparathyroidism and dietary vitamin D deficiency: the requirement for calcium and vitamin D for bone, but not renal responsiveness to PTH. (1977) (8)
Severe hypoglycaemia in Diabetes Control and Complications Trial (1994) (7)
For aggressive preventive management of type 2 diabetes. What is the evidence and is it enough? (1998) (7)
Plasma Insulin Response to an Oral Carbohydrate Solution (1969) (6)
Focal segmental glomerulosclerosis in idiopathic membranous glomerulonephritis: a clinico-pathological and stereological study (2010) (5)
CHAPTER 1 CLASSIFICATION AND DIAGNOSIS OF DIABETES (2016) (5)
Intractable ascites. Surgical management with reduction in secondary hyperaldosteronism. (1976) (4)
Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study (2018) (4)
Discordant Imaging of a Thyroglossal Duct Cyst (1981) (4)
The burden of treatment failure in type 2 diabetes: response to Brown et al. (2005) (4)
Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study (2018) (4)
How Does Pioglitazone Prevent Progression of Impaired Glucose Tolerance to Diabetes? (2013) (3)
Erratum to: Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes (2015) (2)
Coronary Heart Disease Profibrinolytic , Antithrombotic , and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes ( BARI 2 D ) Trial (2011) (2)
Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial". (2014) (2)
Response to Comment on Genuth. Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s Time to Move On! Diabetes Care 2015;38:170–175 (2015) (2)
BARI 2D: A Reanalysis Focusing on Cardiovascular Events. (2019) (2)
DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes (2020) (2)
Response to Comment on: Lachin et al. (2007) The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial: Diabetes 56:1913–1921, 2007 (2008) (2)
Clinical utility of C-peptide measurement in diabetes mellitus. (1996) (2)
Relationship Between Metabolic Control and Complications in Diabetes (2003) (2)
Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis. (2014) (2)
The role of the National Diabetes Advisory Board in diabetes management. (1994) (2)
Abuse of the supplemented fast. (1977) (1)
Intensive Treatment of Type-1 Diabetes The Balance of Benefits and Risks in the DCCT/EDIC Study (2006) (1)
Alanine administration during prolonged fasting. (1971) (1)
Data sharing is desirable, but benefits should not be exaggerated (2015) (1)
Skin Collagen-Linked Fluorescence Predicts Atherosclerosis Progression in the Epidemiology of Diabetes Interventions and Complications (EDIC) Study (2005) (1)
The Role of Diabetes Care and Its Contributions to the Field of Diabetes: A Profile in Progress (2018) (1)
Is NIDDM Just a Receptor Disease? (1981) (1)
Efficacy of instant glucose. (1979) (1)
Summary and perspectives on impaired glucose tolerance. (1996) (1)
Constant intravenous insulin infusion in diabetic ketoacidosis (1973) (1)
United Kingdom prospective diabetes study results are in. (1998) (1)
Mixed messages on systemic therapies for diabetic retinopathy – Authors' reply (2010) (1)
Type II Diabetes Mellitus (2020) (0)
Symposium: obese-hyperglycaemic mice (1972) (0)
Proceedings of the NATIONAL ACADEMY- OF S(C -NCES (2004) (0)
Early termination of the Diabetes Control and Complications Trial (2006) (0)
Insulin secretion in vivo, correlation with insulin resistance. Abstr. (1972) (0)
Effect of somatostatin on carnitine metabolism (1979) (0)
CLINICAL VARIATIONS HOLD IMPORTANT CLUES TO THE UNDERSTANDING AND IMPLEMENTATION OF THE DCCT RESULTS. AUTHORS' REPLIES (1996) (0)
Renal glomerular osteodystrophy. (1972) (0)
Independence of Paget's Disease of Bone from Parathyroid Hormone. (1971) (0)
How should diabetes be treated to minimize the risk of cardiovascular complications (2009) (0)
Renal Osteodystrophy During Chronic Dialysis. (1969) (0)
Cardiovascular function in type 1 diabetes: the DCCT/EDIC Research Group (2009) (0)
in nomad and fruchw-inttrlerant sub+ts (1971) (0)
A medical emancipation proclamation. (2000) (0)
The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes (2016) (0)
Response to Moses (1996) (0)
Laxative-Induced Hypokalemia, Sodium Depletion and Hyperreninemia (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Saul M. Genuth?

Saul M. Genuth is affiliated with the following schools:

George Washington University
McGill University
Case Western Reserve University